Based on the latest data from August 2025, Eli Lilly (LLY) is trading at $732.58, positioning the stock in the undervalued zone below the 14.4x PE multiple threshold of $220.96. This represents a significant discount to all PE boundaries, with the stock trading well below even the lowest valuation band. The current price sits substantially below the value zone (14.4x-36.7x PE), fair value zone (36.7x-58.9x PE), watch zone (58.9x-81.2x PE), overvalued zone (81.2x-103.5x PE), and warning zone (above 125.7x PE). This positioning suggests the stock is trading at historically attractive valuation levels relative to its earnings multiple framework. Analyzing the historical trend reveals a dramatic valuation journey for LLY over the past five years. From 2020 to early 2024, the stock experienced substantial valuation expansion, climbing from the undervalued zone around $128 in January 2020 to peak levels above $900 by late 2024, pushing into the overvalued and warning zones above 81.2x-103.5x PE multiples. The most significant appreciation occurred during 2021-2024, when the stock price increased nearly sevenfold, reflecting strong earnings growth and market optimism. However, since reaching peaks around $909 in September 2024, the stock has undergone a notable correction, declining back toward the undervalued territory. The PE stream boundaries themselves have shown upward movement over time, indicating improving earnings fundamentals, with the 14.4x PE boundary rising from around $87-128 in 2020-2021 to over $220 by 2025, suggesting the company's earnings base has strengthened considerably even as the stock price has retreated from its highs.